Cargando…

A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer

BACKGROUND: The TGF-β pathway plays critical roles in numerous malignancies. Nevertheless, its potential role in prognosis prediction and regulating tumour microenvironment (TME) characteristics require further elucidation in bladder cancer (BLCA). METHODS: TGF-β-related genes were comprehensively s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zhi, Qi, Tiezheng, Li, Xiaowen, Yao, Yiyan, Othmane, Belaydi, Chen, Jinbo, Zu, Xiongbing, Ou, Zhenyu, Hu, Jiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718409/ https://www.ncbi.nlm.nih.gov/pubmed/34975891 http://dx.doi.org/10.3389/fimmu.2021.791924

Ejemplares similares

A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer
por: Liu, Zhi, et al.
Publicado: (2021)

PMEPA1 Is a Prognostic Biomarker That Correlates With Cell Malignancy and the Tumor Microenvironment in Bladder Cancer
por: Qiu, Dongxu, et al.
Publicado: (2021)

Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma
por: Li, Huihuang, et al.
Publicado: (2022)

GATA3 Predicts the Tumor Microenvironment Phenotypes and Molecular Subtypes for Bladder Carcinoma
por: Zhang, Qixin, et al.
Publicado: (2022)

m(6)A-induced lncDBET promotes the malignant progression of bladder cancer through FABP5-mediated lipid metabolism
por: Liu, Peihua, et al.
Publicado: (2022)

5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer
por: Hu, Jiao, et al.
Publicado: (2021)

Emerging Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis
por: Zhang, Chunyu, et al.
Publicado: (2021)

A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer
por: Luo, Cong, et al.
Publicado: (2021)

Filling the gaps in the research about second primary malignancies after bladder cancer: Focus on race and histology
por: Othmane, Belaydi, et al.
Publicado: (2022)

Recurrence factors in patients with Keratinizing squamous metaplasia of the bladder after surgical management: a single-center retrospective study
por: Yi, Zhenglin, et al.
Publicado: (2021)

Effects of Fibrin Clot Inhibitors and Statins on the Intravesical Bacille Calmette–Guérin Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis
por: Cai, Zhiyong, et al.
Publicado: (2021)

N(6)-Methyladenosine in Cancer Immunotherapy: An Undervalued Therapeutic Target
por: Quan, Chao, et al.
Publicado: (2021)

Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer
por: Hu, Jiao, et al.
Publicado: (2021)

An EMT-based risk score thoroughly predicts the clinical prognosis, tumor immune microenvironment and molecular subtypes of bladder cancer
por: Xiao, Zicheng, et al.
Publicado: (2022)

N6-Methyladenosine Writer Gene ZC3H13 Predicts Immune Phenotype and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma
por: Guo, Tao, et al.
Publicado: (2021)

RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma
por: Li, Huihuang, et al.
Publicado: (2021)

THEM6: A Novel Molecular Biomarker Predicts Tumor Microenvironment, Molecular Subtype, and Prognosis in Bladder Cancer
por: Zhao, Xu, et al.
Publicado: (2022)

Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma
por: Deng, Dingshan, et al.
Publicado: (2022)

Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma
por: Cai, Zhiyong, et al.
Publicado: (2022)

BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti‐PD‐1/PD‐L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity
por: Cai, Zhiyong, et al.
Publicado: (2023)

Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study
por: Hu, Jiao, et al.
Publicado: (2022)

Smoking status and pathological response to neoadjuvant chemotherapy among patients with bladder cancer: a pooled analysis
por: He, Tongchen, et al.
Publicado: (2021)

ACSM6 overexpression indicates a non-inflammatory tumor microenvironment and predicts treatment response in bladder cancer: results from multiple real-world cohorts
por: Li, Zhiwei, et al.
Publicado: (2023)

Adjuvant chemotherapy in patients with locally advanced bladder cancer after neoadjuvant chemotherapy and radical cystectomy: a systematic review and pooled analysis
por: Cai, Zhiyong, et al.
Publicado: (2021)

miR-616-5p Promotes Invasion and Migration of Bladder Cancer via Downregulating NR2C2 Expression
por: Ren, Wenbiao, et al.
Publicado: (2021)

Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU)
por: Hosen, S. M. Zahid, et al.
Publicado: (2022)

Silencing of MEG3 attenuated the role of lipopolysaccharides by modulating the miR-93-5p/PTEN pathway in Leydig cells
por: Zhou, Xu, et al.
Publicado: (2021)

Computer-aided diagnosis of prostate cancer based on deep neural networks from multi-parametric magnetic resonance imaging
por: Yi, Zhenglin, et al.
Publicado: (2022)

A novel signature to predict the neoadjuvant chemotherapy response of bladder carcinoma: Results from a territory multicenter real-world study
por: Li, Huihuang, et al.
Publicado: (2022)

Modified Tubeless Ureterocutaneostomy in High-Risk Patients After Radical Cystectomy and its Long-Term Clinical Outcomes
por: Li, Mingyong, et al.
Publicado: (2023)

LPS/TLR4 Signaling Enhances TGF-β Response Through Downregulating BAMBI During Prostatic Hyperplasia
por: He, Yao, et al.
Publicado: (2016)

Control of Dendritic Cell Function Within the Tumour Microenvironment
por: Gupta, Yukti Hari, et al.
Publicado: (2022)

Regulation of epigenetic modifications in the head and neck tumour microenvironment
por: Liu, Huimin, et al.
Publicado: (2022)

S100A5 Attenuates Efficiency of Anti‐PD‐L1/PD‐1 Immunotherapy by Inhibiting CD8(+) T Cell‐Mediated Anti‐Cancer Immunity in Bladder Carcinoma
por: Li, Huihuang, et al.
Publicado: (2023)

The Impact of the Cancer Microenvironment on Macrophage Phenotypes
por: Ham, Sunyoung, et al.
Publicado: (2020)

Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis
por: Cheng, Chunliang, et al.
Publicado: (2021)

GSTM1 and GSTT1 polymorphisms are associated with increased bladder cancer risk: Evidence from updated meta-analysis
por: Yu, Cui, et al.
Publicado: (2016)

Prognosis and Tumour Immune Microenvironment of Patients With Hepatocellular Carcinoma by a Novel Pyroptosis-Related lncRNA Signature
por: Zhang, Ze, et al.
Publicado: (2022)

CLASP2 is involved in the EMT and early progression after transurethral resection of the bladder tumor
por: Zhu, Bisong, et al.
Publicado: (2017)

Upregulation of Atypical Cadherin FAT1 Promotes an Immunosuppressive Tumor Microenvironment via TGF-β
por: Irshad, Khushboo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qcqco7sqp8grudmo6uiv0af9om